Kowa Company Limited

Okihisa Tokuda

Yukiyoshi Yamazaki

Hiroyuki Ishiwata

Ayumu Okuda

Shinsuke Itoh

Takahisa Ogamino

Yoshiharu Miyake

Shin Tanikawa

Tomoaki Fukuda

The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic &#x3b2;-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes. A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt: [wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group;Rand R, which are the same or different, each represent a hydrogen atom, a halogen atom, a halo Calkyl group, a Caryl group, a cyano group, a Calkyl group optionally having a substituent, a Calkenyl group optionally having a substituent, etc.; Rrepresents a hydrogen atom, a Calkyl group optionally having a substituent, etc.; and Rrepresents a hydrogen atom, a halogen atom, a Calkyl group optionally having a substituent, etc.]

Spiroindoline compound, and medicinal agent comprising same

Growing community of inventors

Tokyo, Japan

Okihisa Tokuda